Financial Reports
Related Searches:
Filter by:
256 - 270 of 673 results
November 2, 2010
Clinical Research Services (CRS) revenue was $231.6 million in the quarter (+14%).
Read More »
November 1, 2010
Total specialty pharmaceuticals sales were up 5% in the quarter and medical devices sales increased 8%.
Read More »
October 29, 2010
SP integration continues, and a $1 billion reserve hedges another Vioxx settlement
Read More »
October 28, 2010
Generics, lack of flu pandemic lead to 13% drop in U.S. sales
Read More »
October 27, 2010
Clinical Development Services revenue was $260.3 million in the quarter (+4%).
Read More »
October 26, 2010
Sales in the U.S. were flat at $2.9 billion in the quarter and sales included a $64 million unfavorable impact due to U.S. Health Care Reform.
Read More »
October 26, 2010
Specialty Injectable Pharmaceuticals sales, including U.S. sales of Precedex, meropenem, vancomycin and heparin, help offset the temporary discontinuation of U.S. sales of oxaliplatin (due to a litigation settlement) and the decline in Medication Manageme
Read More »
October 26, 2010
Plavix sales were up 7% to $1.7 billion, but Abilify sales were -7% to $608 million, resulting from changed rebate rates.
Read More »
October 26, 2010
Avonex revenues increased 11% to $644 million in the quarter and Tysabri revenues were up 7% to $221 million.
Read More »
256 - 270 of 673 results
